35 402

Cited 0 times in

Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.

Kim, HJ; Jung, TW; Kang, ES; Kim, DJ; Ahn, CW; Lee, KW; Lee, HC; Cha, BS
Metabolism: clinical and experimental, 56(5):676-685, 2007
Journal Title
Metabolism: clinical and experimental
Treatment with rosiglitazone, a potent peroxisome proliferator-activated receptor (PPAR) gamma agonist, results in lipid storage coupled with reduced release of free fatty acids into the circulation. Many studies have reported that PPAR-gamma agonists increase subcutaneous adiposity but have no effect on visceral fat mass. Perilipin, a family of phosphoproteins that coat intracellular lipid droplets in adipocytes, is essential for enlargement of lipid droplets. Recently, a functional PPAR-responsive element was identified within the murine perilipin gene. We hypothesized that the depot-specific regulation of perilipin by rosiglitazone may be associated with the fat-redistribution and insulin-sensitizing effects of rosiglitazone. After 6 weeks of rosiglitazone treatment in Otusuka Long-Evans Tokushima Fatty rats, an animal model of type 2 diabetes mellitus, we measured changes in adiposity, triglyceride content in liver and muscle, morphology of the pancreas, and perilipin messenger RNA and protein expression in adipose tissue. Rosiglitazone increased subcutaneous adiposity, decreased triglyceride content of liver and muscle, decreased plasma free fatty acids (2107 +/- 507 micromol/L in the placebo group vs 824 +/- 148 micromol/L in the rosiglitazone group; P < .05), and improved insulin resistance. The islets of placebo-treated rats showed hypertrophy and destruction, whereas the islets of rosiglitazone-treated rats showed hypertrophy, but the islet architecture remained intact. Perilipin messenger RNA and protein expression increased in subcutaneous fat, but did not change in visceral fat, after rosiglitazone treatment. In 3T3-L1 cells, rosiglitazone pretreatment decreased lipolysis and increased perilipin protein. In conclusion, increased perilipin expression in subcutaneous fat after rosiglitazone treatment is likely to be a mediator of reduced lipolysis, resulting in lipid storage in subcutaneous fat, fat redistribution, and insulin sensitization.
MeSH terms
3T3-L1 CellsAnimalsBlood Glucose/metabolismBody Weight/drug effectsDiabetes Mellitus, Type 2/bloodDiabetes Mellitus, Type 2/drug therapyDiabetes Mellitus, Type 2/metabolism*Fatty Acids, Nonesterified/bloodGlucose Tolerance TestHypoglycemic Agents/pharmacology*Insulin/bloodInsulin-Secreting Cells/cytologyInsulin-Secreting Cells/drug effectsIntra-Abdominal Fat/drug effects*Intra-Abdominal Fat/metabolismMaleMicePhosphoproteins/biosynthesisPhosphoproteins/geneticsPhosphoproteins/metabolism*RNA/chemistryRNA/geneticsRandom AllocationRatsRats, Inbred OLETFReverse Transcriptase Polymerase Chain ReactionSubcutaneous Fat/drug effects*Subcutaneous Fat/metabolismThiazolidinediones/pharmacology*Triglycerides/metabolismv
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Endocrinology & Metabolism
AJOU Authors
김, 혜진김, 대중이, 관우
Full Text Link
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.